Atossa Therapeutics Announces Full Enrollment of (Z)-Endoxifen Arm of I-SPY 2 Clinical Trial

February 7, 2024

https://www.globenewswire.com/news-release/2024/02/07/2825198/0/en/Atossa-Therapeutics-Announces-Full-Enrollment-of-Z-Endoxifen-Arm-of-I-SPY-2-Clinical-Trial.html

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer, today announced that the (Z)-endoxifen arm of the ongoing Phase 2 I-SPY 2 clinical trial has fully enrolled. In the study, (Z)-endoxifen, Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), is being evaluated as a neoadjuvant treatment for newly diagnosed estrogen receptor-positive (ER+) invasive breast cancer.

Read more at globenewswire.com

Related news for (ATOS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.